ENDPOINTS

Edgewise's heart drug shows promise in Phase 2 trial

Edgewise Therapeutics’ cardiac sarcomere modulator has passed a mid-stage test in patients with a genetic heart muscle disease. The biotech’s EDG-7500 produced “meaningful” reductions in left ventricular outflow tract gradient (LVOT-G), a measure of the ...

Apr 2, 2025 - 12:23
 0
Edgewise's heart drug shows promise in Phase 2 trial
Edgewise Therapeutics’ cardiac sarcomere modulator has passed a mid-stage test in patients with a genetic heart muscle disease. The biotech’s EDG-7500 produced “meaningful” reductions in left ventricular outflow tract gradient (LVOT-G), a measure of the ...
Read More

Tags:

Previous Article

EVs Take 24.4% Share In France — Renault 5 Unassailable?

Next Article

Atsena raises $150M to target rare form of blindness with gene therapy

Related Posts

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Merck KGaA confirms interest in acquiring cancer biotec...

Feb 10, 2025  0

AstraZeneca spotlights first-in-human data for B7-H4-targeting ADC in endometrial cancer

AstraZeneca spotlights first-in-human data for B7-H4-ta...

Mar 17, 2025  0

Biogen plans to open new headquarters in Boston area in 2028

Biogen plans to open new headquarters in Boston area in...

Mar 24, 2025  0